PRJNA800774
Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in Peripheral T-Cell Lymphoma
Expression of the Vav1-Myo1f fusion oncogene alters T-cell differentiation and induces Gata3 positive Th2 PTCL, NOS with a characteristic macrophage signature clinically linked with poor prognosis. Therapeutic targeting of lymphoma-associated macrophages highlights the role of the tumor microenvironment in supporting lymphoma growth and pinpoints to novel therapeutic approaches for the treatment of high-risk PTCL.